Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | PRKCH | P24723 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016025 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL9521214 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL7163178 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL15201698 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL7720721 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL15963880 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL6015980 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL9521223 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL9563973 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG | |
| SCHEMBL12427214 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2SLC2A1PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | claimed |
| JP-10330363-A | — | — | None | — | — | JP | disclosed |
| US-10759823-B2 | Regioselective silyl exchange of per-silylated oligosaccharides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| US-10100074-B2 | Regioselective silyl exchange of per-silylated oligosaccharides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160176909-A1 | REGIOSELECTIVE SILYL EXCHANGE OF PER-SILYLATED OLIGOSACCHARIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2013121264-A1 | SWEET TASTE ENHANCER | FRITO-LAY TRADING COMPANY GMBH (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| EP-1686959-B1 | PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE | HET NL KANKER I THE NETHERLAND (NL) | 2009-06-24 | — | — | EP | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
| CN-1563026-A | Glycoside class compound of phenethyl alcohol alcohol extracted from picria fel-terrae | SANJIN MEDICINES IND CO LTD GU (CN) | 2005-01-12 | — | — | CN | disclosed |
| CN-1153779-C | Acylated derivative of dioscin and its producing process and use | 中国科学院上海有机化学研究所 | 2004-06-16 | — | — | CN | disclosed |
| CN-1322729-A | Acylated derivative of dioscin and its producing process and use | SHANGHAI INST ORGANIC CHEM (CN) | 2001-11-21 | — | — | CN | disclosed |
| JP-H10330363-A | COMPOUND CRPF-2721 | KYOWA HAKKO KOGYO CO LTD | 1998-12-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100074-B2 | Regioselective silyl exchange of per-silylated oligosaccharides | FUT6, SI, FUT5 | PTGS1 4196/4885PTGS2 4318/4885SLC2A1 128/4885 |
| US-20160176909-A1 | REGIOSELECTIVE SILYL EXCHANGE OF PER-SILYLATED OLIGOSACCHARIDES | FUT6, SI, FUT5 | PTGS1 4196/4885PTGS2 4318/4885SLC2A1 128/4885 |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | NPC1L1, SGMS2, SGMS1 | PTGS1 3601/4885PTGS2 3039/4885SLC2A1 30/4885 |
| US-10759823-B2 | Regioselective silyl exchange of per-silylated oligosaccharides | SI, FUT6, OSTC | PTGS1 4154/4885PTGS2 4232/4885SLC2A1 112/4885 |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | SGMS1, SGMS2, CERT1 | PTGS1 4007/4885PTGS2 4087/4885SLC2A1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.